Skip to main content
Premium Trial:

Request an Annual Quote

Marc Jones

Atlas Genetics has announced today that it has appointed Marc Jones as COO and CFO. Jones will lead Atlas' finance and operations functions, as well as new channel development. Prior to Atlas, Jones served as COO and CFO of Good Start Genetics, where he raised successive rounds of capital. Jones also served as CFO of T2 Biosystems, where he oversaw the company's public offering and helped drive commercialization of the company's first FDA IVD product. Previously, Jones was CFO at Crashlytics, Ivenix, and Chil Semiconductor.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.